ACTIONABILITY KNOWLEDGE REPOSITORY ACTIONABILITY CURATION INTERFACE
Update History
Condition: Mucopolysaccharidosis Type II
Gene/Gene Panel: IDS
Context: Pediatric
Date
Status
Release
Outcomes-Interventions
Notes
2022/02/09
Released
1.1.4
P
Early Mortality (GroupA)
Enzyme replacement therapy (ERT) with idursulfase (GroupA) 9CN
Somatic manifestations (as defined by quantitative measures of pulmonary function, 6 minute walk, and hepatosplenomegaly) (GroupA)
Enzyme replacement therapy (ERT) with idursulfase (GroupA) 9CB
Internal system migration associated with MONDO name addition.
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
IDS ⇔ 0010674 MUCOPOLYSACCHARIDOSIS, TYPE II; MPS2
Assertion Pending
Assertion Pending
2022/02/09
Released (Under revision)
1.1.3
P
Early Mortality (GroupA)
Enzyme replacement therapy (ERT) with idursulfase (GroupA) 9CN
Somatic manifestations (as defined by quantitative measures of pulmonary function, 6 minute walk, and hepatosplenomegaly) (GroupA)
Enzyme replacement therapy (ERT) with idursulfase (GroupA) 9CB
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
IDS ⇔ 0010674 MUCOPOLYSACCHARIDOSIS, TYPE II; MPS2
Assertion Pending
Assertion Pending
2022/01/14
Released
1.1.3
P
Early Mortality (GroupA)
Enzyme replacement therapy (ERT) with idursulfase (GroupA) 9CN
Somatic manifestations (as defined by quantitative measures of pulmonary function, 6 minute walk, and hepatosplenomegaly) (GroupA)
Enzyme replacement therapy (ERT) with idursulfase (GroupA) 9CB
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
IDS ⇔ 0010674 MUCOPOLYSACCHARIDOSIS, TYPE II; MPS2
Assertion Pending
Assertion Pending
2022/01/14
Released (Under revision)
1.1.2
P
Early Mortality (GroupA)
Enzyme replacement therapy (ERT) with idursulfase (GroupA) 9CN
Somatic manifestations (as defined by quantitative measures of pulmonary function, 6 minute walk, and hepatosplenomegaly) (GroupA)
Enzyme replacement therapy (ERT) with idursulfase (GroupA) 9CB
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
IDS ⇔ 0010674 MUCOPOLYSACCHARIDOSIS, TYPE II; MPS2
Assertion Pending
Assertion Pending
2021/12/01
Released
1.1.2
P
Early Mortality (GroupA)
Enzyme replacement therapy (ERT) with idursulfase (GroupA) 9CN
Somatic manifestations (as defined by quantitative measures of pulmonary function, 6 minute walk, and hepatosplenomegaly) (GroupA)
Enzyme replacement therapy (ERT) with idursulfase (GroupA) 9CB
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
IDS ⇔ 0010674 MUCOPOLYSACCHARIDOSIS, TYPE II; MPS2
Assertion Pending
Assertion Pending
2021/12/01
Released (Under revision)
1.1.1
P
Early Mortality (GroupA)
Enzyme replacement therapy (ERT) with idursulfase (GroupA) 9CN
Somatic manifestations (as defined by quantitative measures of pulmonary function, 6 minute walk, and hepatosplenomegaly) (GroupA)
Enzyme replacement therapy (ERT) with idursulfase (GroupA) 9CB
2020/04/28
Released
1.1.1
P
Early Mortality (GroupA)
Enzyme replacement therapy (ERT) with idursulfase (GroupA) 9CN
Somatic manifestations (as defined by quantitative measures of pulmonary function, 6 minute walk, and hepatosplenomegaly) (GroupA)
Enzyme replacement therapy (ERT) with idursulfase (GroupA) 9CB
2020/04/28
Released (Under revision)
1.1.0
P
Early Mortality (GroupA)
Enzyme replacement therapy (ERT) with idursulfase (GroupA) 9CN
Somatic manifestations (as defined by quantitative measures of pulmonary function, 6 minute walk, and hepatosplenomegaly) (GroupA)
Enzyme replacement therapy (ERT) with idursulfase (GroupA) 9CB
Internal system migration associated with Gene-Disease scoring groups upgrades.
2019/10/03
Released
1.1.0
P
Early Mortality (GroupA)
Enzyme replacement therapy (ERT) with idursulfase (GroupA) 9CN
Somatic manifestations (as defined by quantitative measures of pulmonary function, 6 minute walk, and hepatosplenomegaly) (GroupA)
Enzyme replacement therapy (ERT) with idursulfase (GroupA) 9CB
Internal system migration associated with Gene-Disease scoring groups upgrades.
2019/08/16
Released
1.0.0
P
Early Mortality
Enzyme replacement therapy (ERT) with idursulfase 9CN
Somatic manifestations (as defined by quantitative measures of pulmonary function, 6 minute walk, and hepatosplenomegaly)
Enzyme replacement therapy (ERT) with idursulfase 9CB
2019/05/16
In Preparation
N/A
We have begun assessment of the Pediatric context for this topic
¤ Powered by BCM's Genboree.